Zacks Research Issues Optimistic Estimate for TEVA Earnings

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) – Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for Teva Pharmaceutical Industries in a research report issued to clients and investors on Wednesday, June 25th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.49 for the quarter, up from their previous forecast of $0.48. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.50 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ FY2026 earnings at $2.61 EPS, Q1 2027 earnings at $0.65 EPS and FY2027 earnings at $2.81 EPS.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a positive return on equity of 45.44% and a negative net margin of 7.74%. The firm had revenue of $3.89 billion for the quarter, compared to analysts’ expectations of $3.99 billion. During the same period last year, the firm earned $0.48 EPS. The company’s quarterly revenue was up 1.9% on a year-over-year basis.

Several other brokerages have also commented on TEVA. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, May 8th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research note on Monday, April 28th. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Thursday, May 22nd. Finally, The Goldman Sachs Group initiated coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a “buy” rating and a $24.00 price objective for the company. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $24.13.

Teva Pharmaceutical Industries Stock Up 1.2%

Teva Pharmaceutical Industries stock opened at $16.76 on Friday. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74. The stock has a market capitalization of $19.22 billion, a PE ratio of -14.57, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. The business has a 50 day simple moving average of $16.66 and a 200-day simple moving average of $17.40. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $22.80.

Insider Activity

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the company’s stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the transaction, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. This represents a 38.32% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.49% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of TEVA. Oarsman Capital Inc. purchased a new position in Teva Pharmaceutical Industries during the 4th quarter valued at about $29,000. Golden State Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $39,000. New Age Alpha Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $43,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in Teva Pharmaceutical Industries during the fourth quarter worth $44,000. Finally, Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter worth $54,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.